ScholarLens Back to search
2003•International Journal of Gynecological CancerOpen access

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

Martin J. Piccart, Kamma Bertelsen, Gavin C.E. Stuart, J. Cassidy, C. Mangioni, Erik Bruun Simonsen, K. James, Samantha L. Kaye, Ignace B. Vergote, R. Blom, Robert N. Grimshaw, R. Atkinson, Ken Swenerton, Claes G. Tropé, Marco Nardi, J. Kærn, Salvatore Tumolo, P.J. Timmers, J.A. Roy, F. Lhoas, B. Lidvall, Monica A. Bacon, A. Birt, Johan Adolph Andersen, Benny Chung-Ying Zee, J. P. Paul, S. Pecorelli, B. Barón, William Patrick McGuire

Open full text 35 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 35 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Paclitaxel, Cisplatin, Oncology, Regimen, Cyclophosphamide, Internal medicine, Chemotherapy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer — Research Paper | ScholarLens